Intellia Therapeutics Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Intellia Therapeutics ha un patrimonio netto totale di $962.6M e un debito totale di $0.0, che porta il suo rapporto debito/patrimonio netto a 0%. Le sue attività totali e le sue passività totali sono rispettivamente $1.2B e $210.7M.

Informazioni chiave

Rapporto debito/patrimonio netto

US$0

Debito

Indice di copertura degli interessi	n/a
Contanti	US$658.11m
Patrimonio netto	US$962.62m
Totale passività	US$210.74m
Totale attività	US$1.17b

Aggiornamenti recenti sulla salute finanziaria

Nessun aggiornamento

Recent updates

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( $710.9M ) di 0JBU superano le sue passività a breve termine ( $105.7M ).

Passività a lungo termine: Le attività a breve termine di 0JBU ( $710.9M ) superano le sue passività a lungo termine ( $105.1M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: 0JBU è esente da debiti.

Riduzione del debito: 0JBU non ha avuto debiti negli ultimi 5 anni.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: 0JBU ha una pista di cassa sufficiente per più di un anno in base al suo attuale flusso di cassa libero.

Previsione Cash Runway: 0JBU ha una liquidità sufficiente per 1.5 anni se il flusso di cassa libero continua a ridursi ai tassi storici del 32.5 % ogni anno.

Intellia Therapeutics Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Intellia Therapeutics, Inc. Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Intellia Therapeutics, Inc. Announces First Clinical Evidence from Ongoing Phase 1 Study That Nexiguran Ziclumeran (nex-z) May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis

Third quarter 2024 earnings released: US$1.34 loss per share (vs US$1.38 loss in 3Q 2023)

Intellia Therapeutics, Inc. Presents Positive Results from the Phase 2 Study of NTLA-2002

Intellia Therapeutics, Inc. Announces Initiation of Haelo Phase 3 Study of Ntla-2002

Second quarter 2024 earnings released: US$1.52 loss per share (vs US$1.40 loss in 2Q 2023)

New major risk - Revenue and earnings growth

Intellia Therapeutics, Inc. Receives Authorization to Initiate Phase 1/2 Clinical Trial of Ntla-3001 for the Treatment of Alpha-1 Antitrypsin Deficiency

Blueallele Corporation Files Lawsuit for Patent Infringement Against Intellia Therapeutics, Inc., for the Unauthorized Use of Blueallele’S Patented Bi-Directional Insertion Templates

Intellia Therapeutics, Inc. Announces Chief Financial Officer Changes

Intellia Therapeutics, Inc. Announces Executive Changes

Intellia Therapeutics to Present the First-Ever Clinical Data from Patients Redosed with an Investigational in Vivo CRISPR Gene Editing Therapy At the Peripheral Nerve Society Annual Meeting 2024

Intellia Therapeutics, Inc. Names Brian Goff to its Board of Directors

Intellia Therapeutics, Inc. Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002

First quarter 2024 earnings released: US$1.13 loss per share (vs US$1.18 loss in 1Q 2023)

Intellia Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024

Intellia Therapeutics, Inc., Annual General Meeting, Jun 12, 2024

Now 25% overvalued

Intellia Therapeutics, Inc. Announces First Patient Dosed in Phase 3 MAGNITUDE Study of NTLA-2001 as Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy

Intellia Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $375.727167 million.

New minor risk - Shareholder dilution

Full year 2023 earnings released: US$5.42 loss per share (vs US$6.16 loss in FY 2022)

New major risk - Revenue and earnings growth

Intellia Therapeutics, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Intellia Therapeutics, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine

President recently sold US$566k worth of stock

Intellia Therapeutics, Inc. Announces Resignation of John F. Crowley from the Board of Directors of Company and Its Committees

Third quarter 2023 earnings released: US$1.38 loss per share (vs US$1.49 loss in 3Q 2022)

New minor risk - Share price stability

Intellia Therapeutics, Inc. Presents New Interim Data from the Ongoing Phase 1 Study of NTLA-2001 At the 4th International ATTR Amyloidosis Meeting

Insufficient new directors

Intellia Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate a Pivotal Phase 3 Trial of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

Second quarter 2023 earnings released: US$1.40 loss per share (vs US$1.33 loss in 2Q 2022)

Intellia Therapeutics, Inc. Appoints Eliana Clark, Phd, Executive Vice President and Chief Technical Officer

Intellia Therapeutics, Inc. Announces New Positive Clinical Data from Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema (HAE)

Intellia Therapeutics, Inc. Announces Resignation of Jean-François Formela as Board Member

First quarter 2023 earnings released: US$1.18 loss per share (vs US$1.97 loss in 1Q 2022)

Full year 2022 earnings released: US$6.16 loss per share (vs US$3.78 loss in FY 2021)

President recently sold US$248k worth of stock

Intellia Therapeutics Presents New Interim Data from First-In-Human Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE)

Intellia Presents Updated Interim Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001

Third quarter 2022 earnings released: US$1.49 loss per share (vs US$0.97 loss in 3Q 2021)

Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema at the 2022 ACAAI Annual Scientific Meeting

Intellia Therapeutics Announces Positive Interim Clinical Data for its Second Systemically Delivered Investigational CRISPR Candidate, NTLA-2002 for the Treatment of Hereditary Angioedema (HAE)

Intellia Therapeutics, Inc. Receives U.S. FDA Orphan Drug Designation for NTLA-2002, an Investigational CRISPR Therapy for the Treatment of Hereditary Angioedema

Intellia Therapeutics, Inc. to Present Interim Clinical Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema At the 2022 Bradykinin Symposium

Second quarter 2022 earnings released: US$1.33 loss per share (vs US$1.01 loss in 2Q 2021)

Intellia Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc. Announces Additional Positive Interim Data from an Ongoing Phase 1 Study of Their Lead Investigational in Vivo Genome Editing Candidate, NTLA-2001

Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the International Liver Congress™ 2022

First quarter 2022 earnings released: US$1.97 loss per share (vs US$0.69 loss in 1Q 2021)

Intellia Therapeutics, Inc. Names Muna Bhanji to Its Board of Directors

Intellia Therapeutics, Inc., Annual General Meeting, Jun 14, 2022

Intellia Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2a Clinical Trial of NTLA-5001 for Treatment of Acute Myeloid Leukemia

Intellia Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc. Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Intellia Therapeutics, Inc. (NasdaqGM : NTLA) acquired Rewrite Therapeutics, Inc. for $200 million.

Intellia Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema

Intellia Therapeutics Announces Expansion of Ongoing Phase 1 Study of NTLA-2001 to Include Adults with Transthyretin Amyloidosis with Cardiomyopathy

Third quarter 2021 earnings released: US$0.97 loss per share (vs US$0.47 loss in 3Q 2020)

Intellia Therapeutics, Inc. announces U.S. Food and Drug Administration accept the investigational new drug (IND) application for NTLA-5001

Second quarter 2021 earnings released: US$1.01 loss per share (vs US$0.61 loss in 2Q 2020)

Intellia Therapeutics, Inc.(NasdaqGM:NTLA) dropped from Russell 3000E Index

Intellia Therapeutics to Present Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2021 Peripheral Nerve Society Annual Meeting

First quarter 2021 earnings released: US$0.69 loss per share (vs US$0.63 loss in 1Q 2020)

Intellia Therapeutics, Inc. Announces the Presentation of New Data from Its CRISPR/Cas9 Platform

Intellia Therapeutics Presents Preclinical Proof of Concept for CRISPR-based In Vivo Editing of Bone Marrow at Keystone eSymposium

Full year 2020 earnings released: US$2.40 loss per share (vs US$2.11 loss in FY 2019)

Revenue misses expectations

Intellia Therapeutics, Inc. Achieves Normal Human Alpha-1 Antitrypsin Protein Levels in Non-Human Primates Through Targeted Gene Insertion for the Treatment of AAT Deficiency

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Analisi della pista di contanti

Scoprire le aziende sane